Vexim Strengthens Its Management Team Appointing Delphine Gricourt as Director of Marketing and Investor Relations

Published: Jan 17, 2013

Toulouse, January 17, 2012 - Vexim (FR0011072602 - ALVXM), a medical device company specializing in minimally invasive treatment of vertebral fractures, has announced the appointment of Delphine Gricourt as Director of Marketing and Investor Relations. Delphine Gricourt has acquired over 20 years of experience in marketing in the medical device and agri-food industries.

Delphine Gricourt started her career in the agri-food industry as Junior Product Manager at Danone in 1992, and moved up to a Product Manager and Group Head position at Saint Mamet. In 1999, she turned to event marketing and worked for the Lucien Barrière Group. From 2003 to 2010, she was Marketing Communications Manager first at Novartis and then at Fresenius laboratories where she developed strategic plans for the medical nutrition product line (class 2 medical device) aimed at hospitals and general practitioners. Following a mission as Project Manager for Marketing and Communication Strategic Review at Valade in 2010, she entered the medical device sector at Paul Boyé Technologies. There, she held the position of Sales & Marketing Director in the Health Department and developed strategic plans for many products including class 1 medical device (orthotics and respiratory equipment).

"We are very pleased to welcome Delphine in our team. Her broad experience along with her sales and marketing expertise will be crucial for the development of Vexim", said Vincent Gardès, CEO, Vexim.

Delphine Gricourt graduated from "l'Ecole Supérieure de Commerce de Montpellier". She is fluent in French, English and Italian.

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February. The Company has specialised in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company currently has 40 staff. It has its own sales teams in France, Germany, Italy, Spain and Switzerland, as well as distributors in Turkey, Argentina and South Africa. Vexim has been listed on NYSE Alternext Paris since 3 May 2012.

For further information, please go to

SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out in a mini-invasive manner, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spinal columns, good medical-expense reimbursement systems in Europe and worldwide patent protection through to 2029.



Vincent Gardès


Tel: +33 5 61 48 48 38


Financial Communications

and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

Alize RP

Press Relations

Caroline Carmagnol

Tel: +33 6 64 18 99 59

Christian Berg

Tel: +33 1 42 68 86 41

Back to news